SCHEMBL3155641

SCHEMBL3155641

COC(=O)c1cccc(C#CC(=O)N2CCN(c3nccs3)CC2)c1

nearest known ligand 0.45

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
SLC6A7 Q99884 1/20 0.45
SCD O00767 1/20 0.41
ALDH1A1 P00352 1/20 0.41
PPARG P37231 1/20 0.41
MAPK10 P53779 1/20 0.41
KMT2A Q03164 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41
RXFP1 Q9HBX9 1/20 0.41
NCOR2 Q9Y618 1/20 0.41
AR P10275 1/20 0.40
NPC1 O15118 1/20 0.40
RAB9A P51151 1/20 0.40
GRM5 P41594 2/20 0.39
GRM1 Q13255 1/20 0.39
ABL1 P00519 1/20 0.39
BCR P11274 1/20 0.39
HSD17B10 Q99714 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3159282 0.90 SLC6A7 (0.43) SLC6A7SCDALDH1A1ARHSD17B10
SCHEMBL3151998 0.89 SLC6A7 (0.47) SLC6A7SCDARGRM5GRM1
SCHEMBL3156515 0.88 SLC6A7 (0.45) SLC6A7SCDARGRM5GRM1
SCHEMBL3148176 0.88 SLC6A7 (0.51) SLC6A7SCDARGRM5GRM1
SCHEMBL3160738 0.88 SLC6A7 (0.48) SLC6A7SCDALDH1A1PPARGMAPK10
SCHEMBL3151961 0.87 SLC6A7 (0.47) SLC6A7SCDARGRM5GRM1
SCHEMBL3151247 0.86 SLC6A7 (0.45) SLC6A7SCDARGRM5GRM1
SCHEMBL3147686 0.86 NPC1 (0.49) SLC6A7SCDALDH1A1KMT2ANPSR1
SCHEMBL3154955 0.85 SLC6A7 (0.47) SLC6A7SCDALDH1A1ARNPC1
SCHEMBL3151765 0.84 SLC6A7 (0.44) SLC6A7SCDALDH1A1KMT2AAR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1765816-B1 SUBSTITUTED 1-PROPIOLYLPIPERAZINES HAVING AN AFFINITY FOR THE MGLUR5 RECEPTOR IN ORDER TO TREAT PAINFUL CONDITIONS GRUENENTHAL GMBH (DE) 2010-03-10 EP claimed
US-7300939-B2 Substituted 1-propiolylpiperazine compounds, their preparation and use GRUENENTHAL GMBH (DE) 2007-11-27 US claimed
US-20070112011-A1 Substituted 1-propiolylpiperazine compounds, their preparation and use GRUENENTHAL GMBH (DE) 2007-05-17 US claimed
US-7300939-B2 Substituted 1-propiolylpiperazine compounds, their preparation and use GRUENENTHAL GMBH (DE) 2007-11-27 US disclosed
US-20070112011-A1 Substituted 1-propiolylpiperazine compounds, their preparation and use GRUENENTHAL GMBH (DE) 2007-05-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070112011-A1 Substituted 1-propiolylpiperazine compounds, their preparation and use GRM5, GRIK5, GRM1 SLC6A7 959/4885SCD 3019/4885ALDH1A1 3746/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.